CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Triamcinolone Acetonide Injection
FDA source answer
FDA source rows are resolved or no longer current.
FDA source statuses: Resolved. First FDA posting: 2021-09-27. Latest FDA row update: 2026-07-31.
FDA lists 1 package records, with companies: Harrow Eye, LLC. Package NDCs: 82667-800-01.
FDA shortage reason: Not stated in the grouped FDA source rows.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Harrow Eye, LLC | 82667-800-01 | Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01) | Not stated | 2026-07-31 |
Source facts
Grouped generic ingredient: Triamcinolone Acetonide Injection · 1 package records
Therapeutic categories: Ophthalmology
Dosage forms: Injection
Routes: OPHTHALMIC
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.